NCT03103542 - Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 29, 2017

Primary Completion Date

September 4, 2019

Study Completion Date

August 31, 2020

Conditions

Hemophilia A

Interventions

BIOLOGICAL

Recombinant coagulation factor (rFVIIIFc)

"rFVIIIFc 200 IU/kg/day during ITI Period and thereafter adjusted according to the Investigator's judgement~administered intravenously."

Trial Locations (12)

Swedish Orphan Biovitrum Research Site, Ljubljana

Swedish Orphan Biovitrum Research site, Gothenburg

Swedish Orphan Biovitrum Research Site, Washington D.C.

Swedish Orphan Biovitrum Research Site, Hamilton

Swedish Orphan Biovitrum Research Site, Vancouver

Swedish Orphan Biovitrum Research Site, Bonn

Swedish Orphan Biovitrum Research Site, Frankfurt am Main

Swedish Orphan Biovitrum Research Site, Mörfelden-Walldorf

Swedish Orphan Biovitrum Research site, Dublin

Swedish Orphan Biovitrum Research Site, Birmingham

Swedish Orphan Biovitrum Research Site, Liverpool

Swedish Orphan Biovitrum Research Site, London